Ameriprise
TRVI icon

Ameriprise’s Trevi Therapeutics TRVI Stock Holding History

Ameriprise’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
622,381
+117,545
+23% +$1.71M ﹤0.01% 1949
2026
Q1 		$6.02M Buy
504,836
+180,664
+56% +$2.02M ﹤0.01% 2314
2025
Q4 		$4.06M Buy
+324,172
New +$3.75M ﹤0.01% 2585
2025
Q3 		– Sell
-154,854
Closed -$847K – 4187
2025
Q2 		$847K Buy
154,854
+36,892
+31% +$230K ﹤0.01% 3337
2025
Q1 		$742K Buy
117,962
+21,178
+22% +$101K ﹤0.01% 3336
2024
Q4 		$399K Buy
96,784
+63,067
+187% +$202K ﹤0.01% 3605
2024
Q3 		$113K Buy
33,717
+18,769
+126% +$55.8K ﹤0.01% 3825
2024
Q2 		$44.5K Sell
14,948
-6,660
-31% -$18.5K ﹤0.01% 3821
2024
Q1 		$74.5K Buy
+21,608
New +$48.2K ﹤0.01% 3799

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Ameriprise's TRVI Position: Q2 2026 in Review

Ameriprise increased its Trevi Therapeutics (TRVI) stake by 23% in Q2 2026, buying an estimated $1.71M and bringing the position to 622,381 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1949.

Ameriprise first reported a position in TRVI in Q1 2024 and has held it in 9 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Ameriprise held 622,381 shares of Trevi Therapeutics worth $11.6M as of Q2 2026.
  • Ameriprise bought 117,545 Trevi Therapeutics shares in Q2 2026, an estimated $1.71M.
  • Trevi Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1949 holding.
  • Ameriprise first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.